We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Companies Join to Create Technology Leader in Molecular Diagnostics

By LabMedica International staff writers
Posted on 22 Apr 2013
Print article
Image: Tuomas Tenkanen, the newly appointed CEO of Mobidiag, with a prototype of the GeneSpress system (Photo courtesy of Mobidiag).
Image: Tuomas Tenkanen, the newly appointed CEO of Mobidiag, with a prototype of the GeneSpress system (Photo courtesy of Mobidiag).
Mobidiag Oy/Ltd, Genewave SAS, and Amplidiag Oy have merged to create Mobidiag (Helsinki, Finland), which will offer integrated, high-multiplex diagnostic tests for infectious diseases.

The transaction was effected as a share exchange, upon which Genewave and Amplidiag became subsidiaries of Mobidiag Oy/Ltd. The new company is headquartered in Helsinki (Finland), with a center of excellence in Paris (France). It now has the diagnostic test pipeline, integrated test platform, leadership, infrastructure, and financial resources to develop and eventually commercialize its automated instrument. This includes a panel of diagnostic tests, capable of identifying a large number of pathogens from a single patient sample.

The new Mobidiag combines Mobidiag’s and Amplidiag’s high-multiplex proprietary diagnostic test portfolios with Genewave’s automated and integrated test platform. The merger was accompanied by a financing round by existing investors, Helsinki University Fund, iXLife, Tutor Invest (Medtech Rahasto Ky), and others, as well as public funding support from the Finnish funding agencies, Tekes and Finnvera, and the European Union (EU).

Mobidiag has built a reference customer base with its current test portfolio and has generated market acceptance in Europe. The automation of Mobidiag’s tests will answer the need of clinical laboratories for automated and integrated solutions for diagnostic testing of severe infectious diseases. Mobidiag’s CE-in vitro diagnostic (IVD) marked Prove-it diagnostic tests enable up to 84 pathogens and antibiotic resistance markers to be detected in a single assay. Current test products are intended for diagnosing bacterial and fungal sepsis, viral central nervous system infections, and bacterial bone and joint infections.

Genewave specializes in the development, manufacturing, and marketing of cutting-edge microarray instrumentation for diagnostic, clinical, and life science research. Genewave’s GeneSpress system is an automated and integrated platform for multiplexed molecular diagnostic tests. The compact system integrates DNA purification, polymerase chain reaction (PCR) amplification, and microarray hybridization and detection into an automated workflow on a single, closed lab-on-chip cartridge. Among other features, the platform incorporates Genewave’s TouchArray optical detection technology for imaging of microarrays.

Amplidiag provides a broad panel of diagnostic tests for infectious diseases. Amplidiag has substantial intellectual property covering testing and nucleic acid extraction methods for contagious gastrointestinal and other serious diseases.

The new CEO of Mobidiag will be Tuomas Tenkanen, the former R&D Director of the diagnostics PCR products provider, Finnzymes Oy, which was acquired by Thermo Fisher Scientific. “The fusion of these three complementary companies creates a unique opportunity to bring forward the next generation of infectious disease diagnostics to dramatically improve global health care,” said the new CEO of Mobidiag.

Related Links:

Mobidiag
Genewave SAS



Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Chemistry Analyzer
MS100
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.